Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2002
08/27/2002US6440992 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
08/27/2002US6440991 Ethers of 7-desmethlrapamycin
08/27/2002US6440990 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
08/27/2002US6440988 Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder
08/27/2002US6440987 Antipruritic
08/27/2002US6440985 Methods for treating viral infections
08/27/2002US6440983 Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
08/27/2002US6440982 Inhibitors of cyclic guanosine monophosphate diesterases
08/27/2002US6440981 Regulating apoptosis in human cells comprising exposing said cells to an effective amount of a 2,9-disubstituted purine-6 one compound
08/27/2002US6440980 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
08/27/2002US6440979 Aryl isoguanines
08/27/2002US6440978 A therapeutical agent for dermatitis comprises 7-amino-3-(halo substituted or unsubstitued benzyl)-1,2,3-tetrahydro-1-phenylpyrido(2,3-d)pyrimidin-2,4-dione
08/27/2002US6440976 Iminopyrimidine NMDA NR2B receptor antagonists
08/27/2002US6440975 Amino acid derivatives, the preparation and use thereof as endothelin antagonists
08/27/2002US6440973 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
08/27/2002US6440972 Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
08/27/2002US6440971 Binuclear complex
08/27/2002US6440969 Certain isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
08/27/2002US6440968 Use of maduraohtalazine derivatives as inhibitors of proinflammatory cytokines
08/27/2002US6440966 Benzenesulfonamide derivatives and their use as MEK inhibitors
08/27/2002US6440965 Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
08/27/2002US6440964 Containing antibiotics such as moxifloxacin; treating infections of microbacterium species microbacterium otitidis and microbacterium alconae
08/27/2002US6440963 Use of selective COX-2 inhibitors for the treatment of urinary incontinence
08/27/2002US6440962 Cardiovascular disorders, antiischemic agents
08/27/2002US6440961 Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
08/27/2002US6440960 An oxygen or sulfure or sulfure oxide or dioxide containing tricyclic compouund useful for treating the disorder manifesting hypersecretion of corticotropin releasing factor
08/27/2002US6440959 Inhibitors of cyclin-dependent kinases
08/27/2002US6440958 Acrylic and propionic acid compounds, intermediates, processes, compositions, and methods
08/27/2002US6440957 Cephalosporines having cyclic aminoguanidine substituents as antibiotics
08/27/2002US6440955 Anti-inflammatory agents
08/27/2002US6440954 Inhibition of vascular smooth muscle cell proliferation
08/27/2002US6440953 Use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion.
08/27/2002US6440952 Phosphono-carboxylate compounds for treating amyloidosis
08/27/2002US6440951 Method for treatment of diabetes
08/27/2002US6440949 Method for promoting the growth of gram-positive bacilli and increasing the acidity in vagina
08/27/2002US6440948 Thiophene A2A receptor agonists
08/27/2002US6440947 Coadministration of an adenosine a2 receptor agonist, e.g., adenosine and heparin or heparin-like compound to improve collateral coronary circulation in patients suffering from myocardial infarction; angiogenisis
08/27/2002US6440943 Mimic and/or modulate the activity of wild-type nucleic acids; the 5' and the 3'-terminal internucleoside linkages are chirally sp and internal internucleoside linkages are chirally rp; resistant to nuclease degradation; psoriasis
08/27/2002US6440941 Derivatives of erythromycin, their preparation process and their use as medicaments
08/27/2002US6440938 Prevention and/or treatment of allergic conditions
08/27/2002US6440937 Competitive inhibitors of trypsin-like serin proteases, especially thrombin and kininogenases such as kallikrein; thrombin inhibitors, anticoagulants, and antiinflammatory agents
08/27/2002US6440935 Such as cecropins and sarcotoxins
08/27/2002US6440931 Conjugated linoleic acid in treatment and prophylaxis of diabetes
08/27/2002US6440929 Pulmonary delivery of active agents
08/27/2002US6440749 Administering a thiazole compound
08/27/2002US6440743 Supplying immobilizated polynucleotides
08/27/2002US6440742 Recombinant AAV vector-based transduction system and use of same
08/27/2002US6440732 Checkpoint/repair genes involved with dna repair prior to replication; aging resistance; cancer therapy
08/27/2002US6440691 Melanins with improved ability to inhibit HIV replication
08/27/2002US6440465 Topical composition for the treatment of psoriasis and related skin disorders
08/27/2002US6440463 Methods for fine powder formation
08/27/2002US6440462 Agglomerates of β-lactam antibiotics and processess for making agglomerates
08/27/2002US6440458 Solid solution of tacrolimus or hydrate and hydroxypropyl cellulose
08/27/2002US6440457 Administering venlafaxine antidepressant time-release agent; sustained release
08/27/2002US6440455 Methods for modulating the axonal outgrowth of central nervous system neurons
08/27/2002US6440454 Supersaturated solution of estradiol, progestogen, and activated silica; outer backing foil and protective lining
08/27/2002US6440453 Transdermal systems for release of 5-HT3 receptor antagonists and their use in anti-emetic treatment
08/27/2002US6440448 Plant and/or animal extract, antioxidant, orally ingestible carrier; antitumor and anticarcinogenic agents; aging resistance; storage stability
08/27/2002US6440446 Agent for anti-osteoporosis
08/27/2002US6440442 Hydrophilic polymer blends used for dry cow therapy
08/27/2002US6440428 Podophyllotoxin preparation containing triglycerides
08/27/2002US6440422 Expressing foreign genes inserted at site of naturally occurring deletion in modified vaccinia virus ankara genome; polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy; encoding antigens as vaccines
08/27/2002US6440419 J chain or portion thereof linked to at least one enzyme inhibitor; specifically binds to basolateral factor; eradi-cation of metastatic or nonpolarized cells; lung, breast, colon, ovarian and prostate carcinoma and endometriosis
08/27/2002US6440418 Variable light and heavy amino acid sequences encoded by nucleic acid sequences; seq id no:24, 25 and 26; rheumatoid arthritis, multiple sclerosis, diabetes, and systemic lupus erythematosus; graft versus host disease; gene therapy
08/27/2002US6440416 Primate antiidiotype antibody or fragment acting as immuno-genic functional mimic; preventive or therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites
08/27/2002US6440413 Selectively destroying subunit a without destroying subunit b of cholera toxin; enzyme with preponderance of exocellular proteinase produced by a culture of streptomyces fradiae; hyperviscosity of intestinal, bronchial and/or genital mucus
08/27/2002US6440410 Normalizing cholesterol and blood pressure; administering natural antioxidant phytochemicals found in fruits and vegetables, including polyphenols, such as chlorogenic acid and ellagic acid, and an enzyme mixture
08/27/2002US6440405 Quaternary ammonium functionalized dendrimers and methods of use therefor
08/27/2002US6440393 Sdministering aerosolized drug in an air mixture containing up to about 10% carbon dioxide gas for increasing the deposition of aerosolized drug in the respiratory tract of an individual or animal
08/27/2002US6440391 Management of snoring by oral administration of dimethyl sulfone
08/27/2002US6440387 For decreasing blood cholesterol levels, thereby decreasing risk for developing alzheimer's disease; for post menopausal women
08/27/2002CA2224738C Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids
08/27/2002CA2167039C Alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them
08/27/2002CA2140013C Pharmaceutical compositions containing galactosylceramides
08/27/2002CA2125888C Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
08/27/2002CA2108898C Blended carboxylic acid sanitizer
08/27/2002CA2104795C 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
08/27/2002CA2101548C Acylamino-alkylidenhydroxy-bisphosphonic acids useful in the therapy of osteoarticular diseases
08/27/2002CA2085354C Ether lipid-nucleoside covalent conjugates
08/27/2002CA2078019C Substance or composition and uses thereof
08/27/2002CA2065889C Increasing the choroidal blood flow
08/27/2002CA2062837C 8-substituted purines as selective adenosine receptor agents
08/27/2002CA2045955C Indole derivatives
08/27/2002CA2033392C A-nor-steroid-3-carboxylic acid derivatives
08/27/2002CA2032311C 2,19-methyleneoxy and 2,19-methylenethio bridged steroids as aromatase and 19-hydroxylase inhibitors
08/27/2002CA2025703C Pulsatile once-a-day delivery systems for minocycline
08/27/2002CA2015838C Method of topically treating acne vulgaris
08/26/2002CA2373363A1 Antitumor and antiviral medications and method for producing the same
08/22/2002WO2002064832A1 Method of examining allergic disease
08/22/2002WO2002064809A2 Process for the preparation of one or more statins by fermentation
08/22/2002WO2002064791A2 Proteins and nucleic acids encoding same
08/22/2002WO2002064790A2 Jfy1 protein induces rapid apoptosis
08/22/2002WO2002064788A2 Compositions and methods relating to lung specific genes and proteins
08/22/2002WO2002064766A2 Bax-responsive genes for drug target identification in yeast and fungi
08/22/2002WO2002064735A2 Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
08/22/2002WO2002064731A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
08/22/2002WO2002064635A1 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
08/22/2002WO2002064618A2 Methods of identifying agents that mediate polypeptide aggregation
08/22/2002WO2002064616A2 Agonists and antagonists of sphingosine-1-phosphate receptors
08/22/2002WO2002064613A1 Genetic therapeutics for obesity and diabetes by targeting cathepsin